

Marc Lipman

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/1197695/publications.pdf>

Version: 2024-02-01

159
papers

6,601
citations

81900

39
h-index

76900

74
g-index

168
all docs

168
docs citations

168
times ranked

9793
citing authors

#	ARTICLE	IF	CITATIONS
1	Protection by BCG Vaccine Against Tuberculosis: A Systematic Review of Randomized Controlled Trials. <i>Clinical Infectious Diseases</i> , 2014, 58, 470-480.	5.8	749
2	“Long-COVID”: a cross-sectional study of persisting symptoms, biomarker and imaging abnormalities following hospitalisation for COVID-19. <i>Thorax</i> , 2021, 76, 396-398.	5.6	636
3	Transcriptional Blood Signatures Distinguish Pulmonary Tuberculosis, Pulmonary Sarcoidosis, Pneumonias and Lung Cancers. <i>PLoS ONE</i> , 2013, 8, e70630.	2.5	254
4	Drug-resistant tuberculosis: time for visionary political leadership. <i>Lancet Infectious Diseases</i> , The, 2013, 13, 529-539.	9.1	243
5	Detectable Changes in The Blood Transcriptome Are Present after Two Weeks of Antituberculosis Therapy. <i>PLoS ONE</i> , 2012, 7, e46191.	2.5	190
6	Development and validation of the ISARIC 4C Deterioration model for adults hospitalised with COVID-19: a prospective cohort study. <i>Lancet Respiratory Medicine</i> , the, 2021, 9, 349-359.	10.7	161
7	Smartphone-enabled video-observed versus directly observed treatment for tuberculosis: a multicentre, analyst-blinded, randomised, controlled superiority trial. <i>Lancet</i> , The, 2019, 393, 1216-1224.	13.7	156
8	The transmission of <i>Mycobacterium tuberculosis</i> in high burden settings. <i>Lancet Infectious Diseases</i> , The, 2016, 16, 227-238.	9.1	149
9	Treatment of Latent Tuberculosis Infection. <i>Annals of Internal Medicine</i> , 2017, 167, 248.	3.9	149
10	Systematic evaluation and external validation of 22 prognostic models among hospitalised adults with COVID-19: an observational cohort study. <i>European Respiratory Journal</i> , 2020, 56, 2003498.	6.7	145
11	Anticipating the impact of the COVID-19 pandemic on TB patients and TB control programmes. <i>Annals of Clinical Microbiology and Antimicrobials</i> , 2020, 19, 21.	3.8	145
12	Prognostic value of interferon- γ release assays and tuberculin skin test in predicting the development of active tuberculosis (UK PREDICT TB): a prospective cohort study. <i>Lancet Infectious Diseases</i> , The, 2018, 18, 1077-1087.	9.1	135
13	Immune reconstitution inflammatory syndrome in HIV. <i>Current Opinion in Infectious Diseases</i> , 2006, 19, 20-25.	3.1	131
14	Direct Whole-Genome Sequencing of Sputum Accurately Identifies Drug-Resistant <i>Mycobacterium tuberculosis</i> Faster than MGIT Culture Sequencing. <i>Journal of Clinical Microbiology</i> , 2018, 56, .	3.9	131
15	Concise whole blood transcriptional signatures for incipient tuberculosis: a systematic review and patient-level pooled meta-analysis. <i>Lancet Respiratory Medicine</i> , the, 2020, 8, 395-406.	10.7	128
16	First evaluation of QuantiFERON-TB Gold Plus performance in contact screening. <i>European Respiratory Journal</i> , 2016, 48, 1411-1419.	6.7	119
17	High mortality in patients with <i>Mycobacterium avium</i> complex lung disease: a systematic review. <i>BMC Infectious Diseases</i> , 2018, 18, 206.	2.9	108
18	Pulmonary <i>Mycobacterium avium-intracellulare</i> is the main driver of the rise in non-tuberculous mycobacteria incidence in England, Wales and Northern Ireland, 2007–2012. <i>BMC Infectious Diseases</i> , 2016, 16, 195.	2.9	106

#	ARTICLE	IF	CITATIONS
19	British HIV Association and British Infection Association guidelines for the treatment of opportunistic infection in HIV-seropositive individuals 2011. <i>HIV Medicine</i> , 2011, 12, 1-5.	2.2	99
20	First independent evaluation of QuantiFERON-TB Plus performance. <i>European Respiratory Journal</i> , 2016, 47, 1587-1590.	6.7	87
21	The Transcriptional Signature of Active Tuberculosis Reflects Symptom Status in Extra-Pulmonary and Pulmonary Tuberculosis. <i>PLoS ONE</i> , 2016, 11, e0162220.	2.5	81
22	Multidrug-resistant tuberculosis (MDR-TB) treatment in the UK: a study of injectable use and toxicity in practice. <i>Journal of Antimicrobial Chemotherapy</i> , 2011, 66, 1815-1820.	3.0	80
23	Health status and quality of life in tuberculosis. <i>International Journal of Infectious Diseases</i> , 2015, 32, 68-75.	3.3	80
24	Paradoxical reactions and immune reconstitution inflammatory syndrome in tuberculosis. <i>International Journal of Infectious Diseases</i> , 2015, 32, 39-45.	3.3	79
25	The application of transcriptional blood signatures to enhance our understanding of the host response to infection: the example of tuberculosis. <i>Philosophical Transactions of the Royal Society B: Biological Sciences</i> , 2014, 369, 20130427.	4.0	75
26	Systematic review, meta-analysis and economic modelling of molecular diagnostic tests for antibiotic resistance in tuberculosis. <i>Health Technology Assessment</i> , 2015, 19, 1-188.	2.8	74
27	The role of CT in case ascertainment and management of COVID-19 pneumonia in the UK: insights from high-incidence regions. <i>Lancet Respiratory Medicine</i> , 2020, 8, 438-440.	10.7	74
28	Blood Transcriptomic Stratification of Short-term Risk in Contacts of Tuberculosis. <i>Clinical Infectious Diseases</i> , 2020, 70, 731-737.	5.8	66
29	Repurposing drugs for treatment of tuberculosis: a role for non-steroidal anti-inflammatory drugs. <i>British Medical Bulletin</i> , 2016, 118, 138-148.	6.9	63
30	The high mental health burden of "Long COVID" and its association with on-going physical and respiratory symptoms in all adults discharged from hospital. <i>European Respiratory Journal</i> , 2021, 57, 2004364.	6.7	62
31	Clinical Aspects of Adult Tuberculosis. <i>Cold Spring Harbor Perspectives in Medicine</i> , 2016, 6, a017848.	6.2	61
32	Resilience and Physical and Mental Well-Being in Adults with and Without HIV. <i>AIDS and Behavior</i> , 2018, 22, 1688-1698.	2.7	58
33	Discovery and validation of a personalized risk predictor for incident tuberculosis in low transmission settings. <i>Nature Medicine</i> , 2020, 26, 1941-1949.	30.7	58
34	Tuberculosis in the UK--time to regain control. <i>BMJ: British Medical Journal</i> , 2011, 343, d4281-d4281.	2.3	55
35	A 380-gene meta-signature of active tuberculosis compared with healthy controls. <i>European Respiratory Journal</i> , 2016, 47, 1873-1876.	6.7	51
36	Clinical utility of existing and second-generation interferon- γ release assays for diagnostic evaluation of tuberculosis: an observational cohort study. <i>Lancet Infectious Diseases</i> , 2019, 19, 193-202.	9.1	47

#	ARTICLE	IF	CITATIONS
37	Observational study to estimate the changes in the effectiveness of bacillus Calmette-Guérin (BCG) vaccination with time since vaccination for preventing tuberculosis in the UK. Health Technology Assessment, 2017, 21, 1-54.	2.8	45
38	The growing impact of HIV infection on the epidemiology of tuberculosis in England and Wales: 1999-2003. Thorax, 2007, 62, 672-676.	5.6	43
39	Determinants of treatment-related paradoxical reactions during anti-tuberculosis therapy: a case control study. BMC Infectious Diseases, 2016, 16, 479.	2.9	42
40	The duration of protection of school-aged BCG vaccination in England: a population-based case-control study. International Journal of Epidemiology, 2018, 47, 193-201.	1.9	41
41	Managing Pulmonary Nontuberculous Mycobacterial Infection. Time for a Patient-centered Approach. Annals of the American Thoracic Society, 2014, 11, 117-121.	3.2	37
42	Adverse Effects and Choice between the Injectable Agents Amikacin and Capreomycin in Multidrug-Resistant Tuberculosis. Antimicrobial Agents and Chemotherapy, 2017, 61, .	3.2	37
43	Does antiretroviral therapy reduce HIV-associated tuberculosis incidence to background rates? A national observational cohort study from England, Wales, and Northern Ireland. Lancet HIV, 2015, 2, e243-e251.	4.7	35
44	Impact of TB on the survival of people living with HIV infection in England, Wales and Northern Ireland. Thorax, 2015, 70, 566-573.	5.6	31
45	Variation in C - reactive protein response according to host and mycobacterial characteristics in active tuberculosis. BMC Infectious Diseases, 2016, 16, 265.	2.9	29
46	High prevalence of latent tuberculosis and bloodborne virus infection in a homeless population. Thorax, 2018, 73, 557-564.	5.6	29
47	Effectiveness of BCG Vaccination Against Mycobacterium tuberculosis Infection in Adults: A Cross-sectional Analysis of a UK-Based Cohort. Journal of Infectious Diseases, 2020, 221, 146-155.	4.0	29
48	Quantitative IFN- γ Release Assay and Tuberculin Skin Test Results to Predict Incident Tuberculosis. A Prospective Cohort Study. American Journal of Respiratory and Critical Care Medicine, 2020, 201, 984-991.	5.6	29
49	Development of a fixed module repertoire for the analysis and interpretation of blood transcriptome data. Nature Communications, 2021, 12, 4385.	12.8	29
50	Amikacin treatment for multidrug resistant tuberculosis: how much monitoring is required?: Table 1. European Respiratory Journal, 2013, 42, 1148-1150.	6.7	28
51	Frequency and significance of indeterminate and borderline Quantiferon Gold TB IGRA results. European Respiratory Journal, 2017, 50, 1701267.	6.7	26
52	What are the most efficacious treatment regimens for isoniazid-resistant tuberculosis? A systematic review and network meta-analysis. Thorax, 2016, 71, 940-949.	5.6	25
53	Latent tuberculosis infection screening and treatment in HIV: insights from evaluation of UK practice. Thorax, 2017, 72, 180-182.	5.6	24
54	Two interferon gamma release assays for predicting active tuberculosis: the UK PREDICT TB prognostic test study. Health Technology Assessment, 2018, 22, 1-96.	2.8	24

#	ARTICLE	IF	CITATIONS
55	Migration and tuberculosis in the UK: targeting screening for latent infection to those at greatest risk of disease: Table A1. <i>Thorax</i> , 2013, 68, 1172-1174.	5.6	23
56	Hepatitis C among vulnerable populations: A seroprevalence study of homeless, people who inject drugs and prisoners in London. <i>Journal of Viral Hepatitis</i> , 2018, 25, 1260-1269.	2.0	23
57	SARS-CoV-2 pandemic: clinical picture of COVID-19 and implications for research. <i>Thorax</i> , 2020, 75, 614-616.	5.6	23
58	Respiratory symptoms in people living with HIV and the effect of antiretroviral therapy: a systematic review and meta-analysis. <i>Thorax</i> , 2017, 72, 355-366.	5.6	22
59	New drugs to treat difficult tuberculous and nontuberculous mycobacterial pulmonary disease. <i>Current Opinion in Pulmonary Medicine</i> , 2019, 25, 271-280.	2.6	21
60	Yield and cost effectiveness of mycobacterial infection detection using a simple IGRA-based protocol in UK subjects with inflammatory bowel disease suitable for anti-TNF± therapy. <i>Journal of Crohn's and Colitis</i> , 2013, 7, 412-418.	1.3	20
61	Decreasing incidence of tuberculosis among heterosexuals living with diagnosed HIV in England and Wales. <i>Aids</i> , 2013, 27, 1151-1157.	2.2	18
62	The changing treatment landscape for MDR/XDR-TB – Can current clinical trials revolutionise and inform a brave new world?. <i>International Journal of Infectious Diseases</i> , 2019, 80, S23-S28.	3.3	18
63	Once Daily Versus Overnight and Symptom Versus Physiological Monitoring to Detect Exacerbations of Chronic Obstructive Pulmonary Disease: Pilot Randomized Controlled Trial. <i>JMIR MHealth and UHealth</i> , 2020, 8, e17597.	3.7	18
64	Identification of the Key Differential Transcriptional Responses of Human Whole Blood Following TLR2 or TLR4 Ligation In-Vitro. <i>PLoS ONE</i> , 2014, 9, e97702.	2.5	17
65	Shortening treatment of tuberculosis: lessons from fluoroquinolone trials. <i>Lancet Infectious Diseases</i> , 2015, 15, 141-143.	9.1	17
66	Tuberculosis treatment outcomes among disadvantaged patients in India. <i>Public Health Action</i> , 2017, 7, 134-140.	1.2	17
67	Diabetes mellitus and latent tuberculosis infection: baseline analysis of a large UK cohort. <i>Thorax</i> , 2019, 74, 91-94.	5.6	17
68	Decreasing cost effectiveness of testing for latent TB in HIV in a low TB incidence area. <i>European Respiratory Journal</i> , 2015, 46, 165-174.	6.7	16
69	Genetic variation in <i>Mycobacterium tuberculosis</i> isolates from a London outbreak associated with isoniazid resistance. <i>BMC Medicine</i> , 2016, 14, 117.	5.5	16
70	Active case finding and treatment adherence in risk groups in the tuberculosis pre-elimination era. <i>International Journal of Tuberculosis and Lung Disease</i> , 2018, 22, 479-487.	1.2	16
71	Carprofen elicits pleiotropic mechanisms of bactericidal action with the potential to reverse antimicrobial drug resistance in tuberculosis. <i>Journal of Antimicrobial Chemotherapy</i> , 2020, 75, 3194-3201.	3.0	16
72	All nonadherence is equal but is some more equal than others? Tuberculosis in the digital era. <i>ERJ Open Research</i> , 2020, 6, 00315-2020.	2.6	16

#	ARTICLE	IF	CITATIONS
73	Validation of Differentially Expressed Immune Biomarkers in Latent and Active Tuberculosis by Real-Time PCR. <i>Frontiers in Immunology</i> , 2020, 11, 612564.	4.8	16
74	Drug resistant TB: UK multicentre study (DRUMS): Treatment, management and outcomes in London and West Midlands 2008–2014. <i>Journal of Infection</i> , 2017, 74, 260-271.	3.3	15
75	Can somatic GATA2 mutation mimic germ line GATA2 mutation?. <i>Blood Advances</i> , 2018, 2, 904-908.	5.2	15
76	Global use, utility, and methods of tele-health in COPD: a health care provider survey. <i>International Journal of COPD</i> , 2019, Volume 14, 1713-1719.	2.3	15
77	Persistent T _H 1 Cell Repertoire Perturbation and T _H 1 Cell Activation in HIV After Long Term Treatment. <i>Frontiers in Immunology</i> , 2021, 12, 634489.	4.8	15
78	Universal HIV testing in London tuberculosis clinics: a cluster randomised controlled trial. <i>European Respiratory Journal</i> , 2013, 41, 627-634.	6.7	14
79	An association between pulmonary <i>Mycobacterium avium</i> -intracellulare complex infections and biomarkers of Th2-type inflammation. <i>Respiratory Research</i> , 2017, 18, 93.	3.6	14
80	Update in Tuberculosis and Nontuberculous Mycobacteria 2017. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2018, 197, 1248-1253.	5.6	14
81	Fluoroquinolones and isoniazid-resistant tuberculosis: implications for the 2018 WHO guidance. <i>European Respiratory Journal</i> , 2019, 54, 1900982.	6.7	14
82	Current and future management of non-tuberculous mycobacterial pulmonary disease (NTM-PD) in the UK. <i>BMJ Open Respiratory Research</i> , 2020, 7, e000591.	3.0	14
83	Respiratory health status is impaired in UK HIV-positive adults with virologically suppressed HIV infection. <i>HIV Medicine</i> , 2017, 18, 604-612.	2.2	13
84	<i>Mycobacterium tuberculosis</i> transmission from patients with drug-resistant compared to drug-susceptible TB: a systematic review and meta-analysis. <i>European Respiratory Journal</i> , 2017, 50, 1701044.	6.7	13
85	Developing a pathway for the diagnosis and management of ocular tuberculosis. The pan-London Ocular tuberculosis Pathway – LOOP. <i>Eye</i> , 2020, 34, 805-808.	2.1	13
86	Effectiveness of peer educators on the uptake of mobile X-ray tuberculosis screening at homeless hostels: a cluster randomised controlled trial. <i>BMJ Open</i> , 2015, 5, e008050.	1.9	12
87	Spot sputum samples are at least as good as early morning samples for identifying <i>Mycobacterium tuberculosis</i> . <i>BMC Medicine</i> , 2017, 15, 192.	5.5	12
88	Community-Acquired Pneumonia in HIV-Infected Individuals. <i>Current Infectious Disease Reports</i> , 2014, 16, 397.	3.0	10
89	Uniting to end the TB epidemic: advances in disease control from prevention to better diagnosis and treatment. <i>BMC Medicine</i> , 2016, 14, 47.	5.5	10
90	Cost effectiveness of testing HIV infected individuals for TB in a low TB/HIV setting. <i>Journal of Infection</i> , 2020, 81, 289-296.	3.3	10

#	ARTICLE	IF	CITATIONS
91	Evaluation of QuantiFERON-TB Gold Plus for Predicting Incident Tuberculosis among Recent Contacts: A Prospective Cohort Study. <i>Annals of the American Thoracic Society</i> , 2020, 17, 646-650.	3.2	10
92	World Tuberculosis Day 2021 Theme "The Clock is Ticking" and the world is running out of time to deliver the United Nations General Assembly commitments to End TB due to the COVID-19 pandemic. <i>International Journal of Infectious Diseases</i> , 2021, 113, S1-S6.	3.3	10
93	Incidence and risk factors for drug intolerance and association with incomplete treatment for tuberculosis: analysis of national case registers for England, Wales and Northern Ireland, 2001-2010: Table A1. <i>Thorax</i> , 2014, 69, 956-958.	5.6	9
94	Non tuberculous mycobacteria pulmonary disease: patients and clinicians working together to improve the evidence base for care. <i>International Journal of Infectious Diseases</i> , 2021, 113, S73-S77.	3.3	9
95	Evaluating knowledge gain from TB leaflets for prison and homeless sector staff: the National Knowledge Service TB pilot. <i>European Journal of Public Health</i> , 2008, 18, 600-603.	0.3	8
96	Airway bacteria and respiratory symptoms are common in ambulatory HIV-positive UK adults. <i>European Respiratory Journal</i> , 2015, 46, 1208-1211.	6.7	8
97	British HIV Association guidelines for the management of tuberculosis in adults living with HIV 2019. <i>HIV Medicine</i> , 2019, 20, s2-s83.	2.2	8
98	A cost comparison of amikacin therapy with bedaquiline, for drug-resistant tuberculosis in the UK. <i>Journal of Infection</i> , 2020, 80, 38-41.	3.3	8
99	Global Epidemiology of NTM Disease (Except Northern America). <i>Respiratory Medicine</i> , 2019, , 163-260.	0.1	8
100	The impact of COVID-19 on global tuberculosis control. <i>Indian Journal of Medical Research</i> , 2021, 153, 404.	1.0	8
101	Collaborative tuberculosis strategy for England. <i>BMJ</i> , The, 2015, 350, h810-h810.	6.0	7
102	Treatment regimens for rifampicin-resistant tuberculosis: highlighting a research gap. <i>International Journal of Tuberculosis and Lung Disease</i> , 2016, 20, 866-869.	1.2	7
103	Latent tuberculosis infection screening and treatment in congregate settings (TB FREE COREA): protocol for a prospective observational study in Korea. <i>BMJ Open</i> , 2020, 10, e034098.	1.9	7
104	Phase I Trial Evaluating the Safety and Immunogenicity of Candidate TB Vaccine MVA85A, Delivered by Aerosol to Healthy M.tb-Infected Adults. <i>Vaccines</i> , 2021, 9, 396.	4.4	7
105	IMPACT study on intervening with a manualised package to achieve treatment adherence in people with tuberculosis: protocol paper for a mixed-methods study, including a pilot randomised controlled trial. <i>BMJ Open</i> , 2019, 9, e032760.	1.9	7
106	Headache in an HIV positive patient: diagnostic challenges and approach to treatment. <i>Clinical Medicine</i> , 2016, 16, 548-550.	1.9	6
107	Injecting drug use predicts active tuberculosis in a national cohort of people living with HIV. <i>Aids</i> , 2017, 31, 2403-2413.	2.2	6
108	Tuberculosis following renal transplantation in England, Wales and Northern Ireland: a national registry-based cohort study. <i>European Respiratory Journal</i> , 2019, 54, 1802245.	6.7	6

#	ARTICLE	IF	CITATIONS
109	The effect of HIV status on the frequency and severity of acute respiratory illness. PLoS ONE, 2020, 15, e0232977.	2.5	6
110	Contact tracing for SARS-CoV-2: what can be learned from other conditions?. Clinical Medicine, 2021, 21, e132-e136.	1.9	6
111	Improved treatment completion for tuberculosis patients: The case for a dedicated social care team. Journal of Infection, 2021, 82, e1-e3.	3.3	6
112	Evidence for a national problem: continued rise in tuberculosis case numbers in urban areas outside London: Figure 1. Thorax, 2012, 67, 275-277.	5.6	5
113	CD4+ cell count responses to antiretroviral therapy are not impaired in HIV-infected individuals with tuberculosis co-infection. Aids, 2015, 29, 1363-1368.	2.2	5
114	Trends in, and factors associated with, HIV infection amongst tuberculosis patients in the era of anti-retroviral therapy: a retrospective study in England, Wales and Northern Ireland. BMC Medicine, 2018, 16, 85.	5.5	5
115	Revolutionary new treatment regimens for multidrug-resistant tuberculosis. Lancet Infectious Diseases, The, 2019, 19, 233-234.	9.1	5
116	Discordance in latent tuberculosis (TB) test results in patients with end-stage renal disease. Public Health, 2019, 166, 34-39.	2.9	5
117	Reducing loss to follow-up during treatment for drug-resistant tuberculosis. European Respiratory Journal, 2019, 53, 1802268.	6.7	5
118	Descriptive account of 18 adults with known HIV infection hospitalised with SARS-CoV-2 infection. Sexually Transmitted Infections, 2020, 97, sextrans-2020-054660.	1.9	5
119	A Controlled Trial of the Knowledge Impact of Tuberculosis Information Leaflets among Staff Supporting Substance Misusers: Pilot Study. PLoS ONE, 2011, 6, e20875.	2.5	5
120	Do we need bacteriological confirmation of cure in uncomplicated tuberculosis?: Table 1â€œ. European Respiratory Journal, 2013, 42, 860-863.	6.7	4
121	Increasing incidence of HIVâ€œ-associated tuberculosis in Romanian injecting drug users. HIV Medicine, 2018, 19, 316-323.	2.2	4
122	Enrichment of the airway microbiome in people living with HIV with potential pathogenic bacteria despite antiretroviral therapy. EClinicalMedicine, 2020, 24, 100427.	7.1	4
123	Screening for tuberculosis among high-risk groups attending London emergency departments: a prospective observational study. European Respiratory Journal, 2021, 57, 2003831.	6.7	4
124	Interferon Î±-release assays for detecting latent tuberculosis infection in patients scheduled for anti-TNFÎ± therapy. Frontline Gastroenterology, 2011, 2, 26-31.	1.8	3
125	Personalizing therapy for multidrug resistant TB: the potential of Rapid Whole Genome Sequencing. Expert Review of Anti-Infective Therapy, 2016, 14, 1-3.	4.4	3
126	Occupational Tuberculosis despite Minimal Nosocomial Contact in a Health Care Worker Undergoing Treatment with a Tumor Necrosis Factor Inhibitor. Annals of the American Thoracic Society, 2016, 13, 2275-2277.	3.2	3

#	ARTICLE	IF	CITATIONS
127	Hepatitis C virus infection in vulnerable populations: a seroprevalence study of homeless, people who inject drugs and prisoners in London, UK. <i>Lancet, The</i> , 2017, 390, S18.	13.7	3
128	Protecting the vulnerable: SARS-CoV-2 vaccination in immunosuppressed patients with interstitial lung disease. <i>Lancet Respiratory Medicine</i> , 2021, 9, 947-949.	10.7	3
129	Management and control of tuberculosis control in socially complex groups: a research programme including three RCTs. <i>Programme Grants for Applied Research</i> , 2020, 8, 1-76.	1.0	3
130	Commemorating World Tuberculosis Day 2015. <i>International Journal of Infectious Diseases</i> , 2015, 32, 1-4.	3.3	2
131	Respiratory co-morbidities in people with HIV. <i>Lancet Infectious Diseases, The</i> , 2016, 16, 21.	9.1	2
132	Access to influenza immunisation services by HIV-positive patients in the UK. <i>Influenza and Other Respiratory Viruses</i> , 2018, 12, 544-546.	3.4	2
133	Chest pain and a left parasternal soft tissue swelling in an immunocompetent refugee with disseminated tuberculosis. <i>International Journal of Infectious Diseases</i> , 2020, 90, 116-118.	3.3	2
134	Poor Outcome of Central Nervous System Invasive Aspergillosis in HIV Infection Despite Galactomannan-Based Diagnosis. <i>Infectious Diseases in Clinical Practice</i> , 2011, 19, 299-302.	0.3	1
135	A postgraduate qualification in tuberculosis – Message in a bottle. <i>International Journal of Infectious Diseases</i> , 2020, 92, S100-S102.	3.3	1
136	Who gets a laboratory positive diagnosis of <i>Mycoplasma pneumoniae</i> : A 10-year retrospective analysis. <i>Clinical Infection in Practice</i> , 2021, 10, 100070.	0.5	1
137	S29 – A randomised controlled trial comparing smartphone enabled remote video observation with direct observation of treatment for tuberculosis. , 2017, , .		0
138	HIV and respiratory illness in the antiretroviral therapy era. <i>Annals of Research Hospitals</i> , 0, 1, 43-43.	0.0	0
139	007 – Immunoglobulin G4 related disease with isolated pulmonary involvement in a patient with seropositive rheumatoid arthritis taking adalimumab. <i>Rheumatology</i> , 2018, 57, .	1.9	0
140	Systematic identification and referral of smokers attending HIV ambulatory care highlights the failure of current service provision in an at-risk population. <i>BMJ Open Respiratory Research</i> , 2019, 6, e000395.	3.0	0
141	Non-tuberculous mycobacterial lung disease in general practice. <i>Practice Nursing</i> , 2019, 30, 432-437.	0.1	0
142	Urgent call for greater multilateralism and coordination of covid-19 trials. <i>BMJ, The</i> , 2020, 370, m2666.	6.0	0
143	Post-Tuberculosis Infections and Chronic Lung Disease. , 2021, , 283-291.		0
144	Tuberculosis in People Living with HIV. , 2021, , 213-220.		0

#	ARTICLE	IF	CITATIONS
145	Health economic analyses of latent tuberculosis infection screening and preventive treatment among people living with HIV in lower tuberculosis incidence settings: a systematic review. Wellcome Open Research, 0, 6, 51.	1.8	0
146	Implementing and evaluating standardised tuberculosis incident management for nonhousehold contacts in a large clinical network. ERJ Open Research, 2021, 7, 00270-2021.	2.6	0
147	Exploring a combined biomarker for tuberculosis treatment response: protocol for a prospective observational cohort study. BMJ Open, 2021, 11, e052885.	1.9	0
148	Provision of influenza immunisation for UK HIV positive adults. , 2016, , .		0
149	Attitudes to smoking and quitting in UK HIV positive adults: Would more education help?. , 2016, , .		0
150	Evaluation of the GenoType [®] NTM DR for Subspecies Identification and Determination of Drug Resistance in Clinical M. abscessus Isolates. Clinical Microbiology (Los Angeles, Calif), 2017, 06, .	0.2	0
151	High frequency of unexplained breathlessness among UK HIV positive adults. , 2017, , .		0
152	Do higher quantitative interferon gamma release assay or tuberculin skin test results help to predict incident tuberculosis? Data from the UK PREDICT study. , 2019, , .		0
153	The impact of COVID-19 on global tuberculosis control. Indian Journal of Medical Research, 2021, 153, 404-408.	1.0	0
154	A UK cost comparison of amikacin therapy with bedaquiline, for drug resistant tuberculosis. , 2020, , .		0
155	Randomised controlled trial to evaluate the effectiveness of using the RD-1-based C-Tb skin test as a replacement for blood-based interferon- γ release assay for detection of, and initiation of preventive treatment for, tuberculosis infection: RID-TB:Dx study protocol. BMJ Open, 2021, 11, e050595.	1.9	0
156	The effect of HIV status on the frequency and severity of acute respiratory illness. , 2020, 15, e0232977.		0
157	The effect of HIV status on the frequency and severity of acute respiratory illness. , 2020, 15, e0232977.		0
158	The effect of HIV status on the frequency and severity of acute respiratory illness. , 2020, 15, e0232977.		0
159	The effect of HIV status on the frequency and severity of acute respiratory illness. , 2020, 15, e0232977.		0